Investigation Report on China's Temozolomide Market 2021-2025

Investigation Report on China’s Temozolomide Market 2021-2025

$2600 – $3900

Due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the sales value of Temozolomide in the Chinese market decreased to CNY793 million in 2020 and the CAGR of Temozolomide in sales value from 2016 to 2020 is 9.04%.

SKU: 2107542 Category: Tags: , , , , , , , , , , , , , , , , , , , , , ,

Description

Temozolomide is a second-generation alkylating agent. It is an oral chemotherapeutic drug used to treat brain cancers such as adult malignant glioma and malignant melanoma. It was developed by Merck & Co., Inc. The drug was approved to enter the Chinese market under the trade name TEMODAL in 2007. By 2020, Temozolomide has been included in China’s Class B medical insurance. There are many manufacturers in the Chinese market in 2020, among which Merck Sharp & Dohme Ltd is the main manufacturer.

According to CRI’s market research, the sales value of Temozolomide in the Chinese market increased year by year from 2016 to 2019. Due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the sales value of Temozolomide in the Chinese market decreased to CNY793 million in 2020 and the CAGR of Temozolomide in sales value from 2016 to 2020 is 9.04%.

CRI expects that with the relief of COVID-19, the sales value of Temozolomide in the Chinese market will have a restorative growth from 2021 to 2025. In addition, as the incidence of primary brain cancer increases, other cancers can cause secondary brain cancer. Therefore, with the widespread use of digital electronic products and the increase in the incidence of other cancers, the incidence of brain cancer is also increasing year by year, the sales value and sales volume of Temozolomide for the treatment of brain cancer will continue to increase. At the same time, Temozolomide has the characteristics of easily penetrating the blood-cerebrospinal fluid barrier and mild adverse reactions. CRI predicts that the sales value and sales volume of Temozolomide in the Chinese market will have room for increase from 2021 to 2025.

 

Topics Covered:

  • -The impact of COVID-19 on China’s Temozolomide market
  • – Sales value of China’s Temozolomide 2016-2020
  • – Competitive landscape of China’s Temozolomide market
  • – Prices of Temozolomide in China
  • – Prices of Temozolomide in China by regions and manufacturers
  • – Analysis on factors affecting the development of China’s Temozolomide market
  • – Prospect of China’s Temozolomide market from 2021 to 2025

Additional information

Publisher

Geography Covered

Date Published

Pages

Charts

Format

Base Year

2016
Base Market Size

560.57
Currency/Unit

CNY million
Forecast Year

2025
Market Size Forecast

1396.80
CAGR

10.68%

Table of Contents

1 Relevant Concepts of Temozolomide

  • 1.1 Indications for Temozolomide
  • 1.2 Development of Temozolomide in China
  • 1.3 Governmental Approval of Temozolomide in China
  • 1.4 The Impact of COVID-19 on Temozolomide sales in China

 

2 Sales of Temozolomide in China, 2016-2020

  • 2.1 Sales Value of Temozolomide
  • 2.1.1 Overall Sales Value
  • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Temozolomide
  • 2.2.1 Overall Sales Volume
  • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Temozolomide by Dosage Form in China, 2016-2020
  • 2.3.1 Injection
  • 2.3.2 Analysis of Other Dosage Forms

 

3 Analysis of Major Temozolomide Manufacturers in China in 2020

  • 3.1 Analysis of Market Share of Major Temozolomide Manufacturers
  • 3.1.1 Investigation on Market Share by Sales Value
  • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 Merck Sharp & Dohme Ltd
  • 3.2.1 Enterprise Profile
  • 3.2.2 Sales of TEMODAL (Merck Sharp & Dohme Ltd’s Temozolomide) in China
  • 3.3  Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
  • 3.3.1 Enterprise Profile
  • 3.3.2 Sales of Diqing (Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.’s Temozolomide) in China
  • 3.4 Beijing Shuanglu Pharmaceutical Co., Ltd.
  • 3.4.1 Enterprise Profile
  • 3.4.2 Sales of Jiaoning (Beijing Shuanglu Pharmaceutical Co., Ltd. ’s Temozolomide) in China
  • 3.5 Schering-Plough Canada
  • 3.5.1 Enterprise Profile
  • 3.5.2 Sales of TEMODAL (Schering-Plough Canada’s Temozolomide) in China
  • 3.6 Jiangsu Hengrui Medicine Company Ltd.
  • 3.6.1 Enterprise Profile
  • 3.6.2 Sales of Jiangsu Hengrui Medicine Company Ltd.’s Temozolomide in China

 

4 Prices of Temozolomide for Different Manufacturers in China, 2020-2021

  • 4.1 Merck Sharp & Dohme Ltd (TEMODAL)
  • 4.2 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (Diqing)
  • 4.3 Beijing Shuanglu Pharmaceutical Co., Ltd.  (Jiaoning)
  • 4.4 Schering-Plough Canada (TEMODAL)
  • 4.5 Jiangsu Hengrui Medicine Company Ltd.

 

5 Prospect of Chinese Temozolomide drug Market, 2021-2025

  • 5.1 Influential Factors of Chinese Temozolomide Market Development
  • 5.1.1 The Impact of COVID-19 on Chinese Temozolomide Market
  • 5.1.2 Market Drivers and Opportunities
  • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

 

List of Charts

  • Chart Patent Information About Temozolomide Injection Registration in China
  • Chart Sales Value of Temozolomide Injection over the World
  • Chart Sales Value of Temozolomide Injection in China, 2016-2020
  • Chart Sales Value of Temozolomide Injection in China by Region, 2016-2020
  • Chart Sales Volume of Temozolomide Injection in China, 2016-2020
  • Chart Sales Volume of Temozolomide Injection in China by Region, 2016-2020
  • Chart Market Share by Sales Value of Top Temozolomide Manufacturers in China, 2016-2020
  • Chart Sales Value and Volume of TEMODAL (Merck Sharp & Dohme Ltd’s Temozolomide) in China, 2016-2020
  • Chart Sales Value and Volume of Diqing in China, 2016-2020
  • Chart Sales Value and Volume of Jiaoning in China, 2016-2020
  • Chart Sales Value and Volume of TEMODAL (Schering-Plough Canada’s Temozolomide) in China, 2016-2020
  • Chart Sales Value and Volume of Jiangsu Hengrui Medicine Company Ltd.’s Temozolomide in China, 2016-2020
  • Chart Referential Prices of TEMODAL (Merck Sharp & Dohme Ltd’s Temozolomide) in China, 2020-2021
  • Chart Referential Prices of Diqing in China, 2020-2021
  • Chart Referential Prices of Jiaoning in China, 2020-2021
  • Chart Referential Prices of TEMODAL (Schering-Plough Canada’s Temozolomide) in China, 2020-2021
  • Chart Referential Prices of Jiangsu Hengrui Medicine Company Ltd.’s Temozolomide in China, 2020-2021
  • Chart Forecast on Sales Value of Temozolomide in China, 2021-2025
  • Chart Forecast on Sales Volume of Temozolomide in China, 2021-2025

Related products